Cargando…

EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY

PURPOSE: To analyze the effects of a dexamethasone intravitreal implant (DEX; Ozurdex 700 μg; Allergan) administered immediately after cataract surgery in diabetic patients. METHODS: This prospective, single-arm, open label study (NCT01748487 at ClinicalTrials.gov) involved Type 2 diabetic patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Calvo, Pilar, Ferreras, Antonio, Al Adel, Fadwa, Dangboon, Wantanee, Brent, Michael H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Retina 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841849/
https://www.ncbi.nlm.nih.gov/pubmed/28196056
http://dx.doi.org/10.1097/IAE.0000000000001552
_version_ 1783304811609849856
author Calvo, Pilar
Ferreras, Antonio
Al Adel, Fadwa
Dangboon, Wantanee
Brent, Michael H.
author_facet Calvo, Pilar
Ferreras, Antonio
Al Adel, Fadwa
Dangboon, Wantanee
Brent, Michael H.
author_sort Calvo, Pilar
collection PubMed
description PURPOSE: To analyze the effects of a dexamethasone intravitreal implant (DEX; Ozurdex 700 μg; Allergan) administered immediately after cataract surgery in diabetic patients. METHODS: This prospective, single-arm, open label study (NCT01748487 at ClinicalTrials.gov) involved Type 2 diabetic patients with at least mild diabetic retinopathy (DR) who underwent cataract surgery and DEX insertion after phacoemulsification, and intraocular lens implantation were enrolled. Best-corrected visual acuity and central retinal thickness (CRT) measured by spectral-domain optical coherence tomography were recorded at 1 week preoperatively, and 1 week, 1 month, and 3 months after surgery. Adverse events were also recorded. RESULTS: Twenty-four eyes of 24 patients (17 [70.8%] men; mean age 63.7 ± 8.7 years) with mild nonproliferative DR (41.7%), moderate nonproliferative DR (33.3%), severe nonproliferative DR (16.7%), or treated proliferative DR (8.3%) were selected. After DEX treatment, mean CRT changed from 241.1 μm (95% confidence interval, 227.5–254.6 μm) at baseline to 236.9 μm (95% confidence interval, 223.9–249.9 μm) at 1 week (P = 0.09), 238.9 μm (95% confidence interval, 225.5–252.3 μm) at 1 month (P = 0.44), and 248 μm (95% confidence interval, 232.4–260.8 μm) at 3 months (P = 0.15). No eyes showed a postoperative increase >50 μm in the CRT at any visit. A 10% increase in CRT was found in 8.3% of eyes. Mean best-corrected visual acuity significantly improved from 0.37 (20/50) at baseline to 0.19 (20/30) at 1 week, 0.12 (20/25) at 1 month, and 0.12 (20/25) at 3 months (P < 0.001 for each comparison). Mean intraocular pressure before surgery was 13.8 mmHg, and none of the patients developed an intraocular pressure ≥22 mmHg at any visit. None of the patients developed any serious adverse events during the follow-up. CONCLUSION: These short-term results suggest that a single DEX injection intraoperatively after phacoemulsification could avoid an increase in CRT after cataract surgery in diabetic patients.
format Online
Article
Text
id pubmed-5841849
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Retina
record_format MEDLINE/PubMed
spelling pubmed-58418492018-03-20 EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY Calvo, Pilar Ferreras, Antonio Al Adel, Fadwa Dangboon, Wantanee Brent, Michael H. Retina Original Study PURPOSE: To analyze the effects of a dexamethasone intravitreal implant (DEX; Ozurdex 700 μg; Allergan) administered immediately after cataract surgery in diabetic patients. METHODS: This prospective, single-arm, open label study (NCT01748487 at ClinicalTrials.gov) involved Type 2 diabetic patients with at least mild diabetic retinopathy (DR) who underwent cataract surgery and DEX insertion after phacoemulsification, and intraocular lens implantation were enrolled. Best-corrected visual acuity and central retinal thickness (CRT) measured by spectral-domain optical coherence tomography were recorded at 1 week preoperatively, and 1 week, 1 month, and 3 months after surgery. Adverse events were also recorded. RESULTS: Twenty-four eyes of 24 patients (17 [70.8%] men; mean age 63.7 ± 8.7 years) with mild nonproliferative DR (41.7%), moderate nonproliferative DR (33.3%), severe nonproliferative DR (16.7%), or treated proliferative DR (8.3%) were selected. After DEX treatment, mean CRT changed from 241.1 μm (95% confidence interval, 227.5–254.6 μm) at baseline to 236.9 μm (95% confidence interval, 223.9–249.9 μm) at 1 week (P = 0.09), 238.9 μm (95% confidence interval, 225.5–252.3 μm) at 1 month (P = 0.44), and 248 μm (95% confidence interval, 232.4–260.8 μm) at 3 months (P = 0.15). No eyes showed a postoperative increase >50 μm in the CRT at any visit. A 10% increase in CRT was found in 8.3% of eyes. Mean best-corrected visual acuity significantly improved from 0.37 (20/50) at baseline to 0.19 (20/30) at 1 week, 0.12 (20/25) at 1 month, and 0.12 (20/25) at 3 months (P < 0.001 for each comparison). Mean intraocular pressure before surgery was 13.8 mmHg, and none of the patients developed an intraocular pressure ≥22 mmHg at any visit. None of the patients developed any serious adverse events during the follow-up. CONCLUSION: These short-term results suggest that a single DEX injection intraoperatively after phacoemulsification could avoid an increase in CRT after cataract surgery in diabetic patients. Retina 2018-03 2017-02-10 /pmc/articles/PMC5841849/ /pubmed/28196056 http://dx.doi.org/10.1097/IAE.0000000000001552 Text en This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Original Study
Calvo, Pilar
Ferreras, Antonio
Al Adel, Fadwa
Dangboon, Wantanee
Brent, Michael H.
EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY
title EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY
title_full EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY
title_fullStr EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY
title_full_unstemmed EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY
title_short EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY
title_sort effect of an intravitreal dexamethasone implant on diabetic macular edema after cataract surgery
topic Original Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841849/
https://www.ncbi.nlm.nih.gov/pubmed/28196056
http://dx.doi.org/10.1097/IAE.0000000000001552
work_keys_str_mv AT calvopilar effectofanintravitrealdexamethasoneimplantondiabeticmacularedemaaftercataractsurgery
AT ferrerasantonio effectofanintravitrealdexamethasoneimplantondiabeticmacularedemaaftercataractsurgery
AT aladelfadwa effectofanintravitrealdexamethasoneimplantondiabeticmacularedemaaftercataractsurgery
AT dangboonwantanee effectofanintravitrealdexamethasoneimplantondiabeticmacularedemaaftercataractsurgery
AT brentmichaelh effectofanintravitrealdexamethasoneimplantondiabeticmacularedemaaftercataractsurgery